GlassScriptPhysician profile
Nora I Valdes
NPI 1124069406
$6,944.08
in general payments reported to CMS, 2019-2025
32 companies · $908 in 2025
The $908 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $799 · 2021: $881 · 2022: $827 · 2023: $1,025 · 2024: $1,000 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.50 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,063.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $860.16 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $758.07 | 2022-2025 | |
| Amgen INC. | $551.25 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $510.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $213.17 | 2020-2025 | Trintellix |
| Pfizer INC. | $210.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.51 | 2020-2025 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $121.15 | 2021 | |
| Supernus Pharmaceuticals, INC. | $107.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $97.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $87.15 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.96 | 2019-2022 | |
| Shire North American Group INC | $65.15 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $59.75 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $59.08 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $57.57 | 2022-2024 | Rexulti, Abilify Maintena |
| Kowa Pharmaceuticals America, INC. | $54.51 | 2022 | |
| Exact Sciences Corporation | $50.02 | 2025 | The Cologuard Plus Collection Kit |
| Alk-Abello, INC | $48.77 | 2024 | Odactra, Grastek, Ragwitek |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.04 | 2023-2025 | Caplyta |
| Bausch Health US, LLC | $45.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.85 | 2019-2020 | |
| Medtronic, INC. | $20.62 | 2024 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $18.64 | 2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.58 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.99 | 2021 | |
| Corium, LLC | $13.49 | 2023 | Azstarys |
| Si-Bone, INC. | $12.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.